Herpes simplex type 2 infections - An update

Disease-a-Month

Volumn 46, Issue 5, 2000, Pages 328-359

  Marques, Adriana R ^a   Straus, Stephen E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; VIRUS VACCINE; ACICLOVIR; CIDOFOVIR; FAMCICLOVIR; HERPES VACCINE; VALACICLOVIR;

DISEASE TRANSMISSION; DRUG RESISTANCE; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNOLOGY; MALE; NEWBORN; PATHOPHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; RISK FACTOR; VIROLOGY; CLINICAL TRIAL; DRUG EFFICACY; HERPES VIRUS INFECTION; IMMUNE RESPONSE; NEWBORN DISEASE; NONHUMAN; VIRUS GENOME; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS; VIRAL VACCINES;

EID: 0034077717     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (141)

1. Hutfield DC. History of herpes genitalis. Br J Vener Dis 1966;42:263-8.
2. Dolan A, Jamieson FE, Cunningham C, et al. The genome sequence of herpes simplex virus type 2. J Virol 1998;72:2010-21.
3. McGeoch DJ, Cook S, Dolan A, et al. Molecular phylogeny and evolutionary timescale for the family of mammalian herpesviruses. J Mol Biol 1995;247:443-58.
4. McGeoch DJ, Cook S. Molecular phylogeny of the alphaherpesvirinae subfamily and a proposed evolutionary timescale. J Mol Biol 1994;238:9-22.
5. Herold BC, Visalli RJ, Susmarski N, et al. Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface heparan sulphate and glycoprotein B. J Gen Virol 1994;75:1211-22.
6. Spear PG, Shieh MT, Herold BC, et al. Heparan sulfate glycosaminoglycans as primary cell surface receptors for herpes simplex virus. Adv Exp Med Biol 1992;313:341-53.
7. Shieh MT, WuDunn D, Montgomery RI, et al. Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. J Cell Biol 1992;116:1273-81.
8. Montgomery RI, Warner MS, Lum BJ, et al. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 1996;87:427-36.
9. Whitbeck JC, Peng C, Lou H, et al. Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry. J Virol 1997;71:6083-93.
10. Geraghty RJ, Krummenacher C, Cohen GH, et al. Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science 1998;280:1618-20.
11. Warner MS, Geraghty RJ, Martinez WM, et al. A cell surface protein with herpesvirus entry activity (HveB) confers susceptibility to infection by mutants of herpes simplex virus type 1, herpes simplex virus type 2, and pseudorabies virus. Virology 1998;246:179-89.
12. Block TM, Deshmane S, Masonis J, et al. An HSV LAT null mutant reactivates slowly from latent infection and makes small plaques on CV-1 monolayers. Virology 1993;192:618-30.
13. Bloom DC, Hill JM, Devi-Rao G, et al. A 348-base-pair region in the latency-associated transcript facilitates herpes simplex virus type 1 reactivation. J Virol 1996;70:2449-59.
14. Lekstrom-Himes JA, Pesnicak L, Straus SE. The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks. J Virol 1998;72:2760-4.
15. Sawtell NM, Poon DK, Tansky CS, et al. The latent herpes simplex virus type 1 genome copy number in individual neurons is virus strain specific and correlates with reactivation. J Virol 1998;72:5343-50.
16. Maggioncalda J, Mehta A, Su YH, et al. Correlation between herpes simplex virus type 1 rate of reactivation from latent infection and the number of infected neurons in trigeminal ganglia. Virology 1996;225:72-81.
17. Yoshikawa T, Hill JM, Stanberry LR, et al. The characteristic site-specific reactivation phenotypes of HSV-1 and HSV-2 depend upon the latency-associated transcript region. J Exp Med 1996;184:659-64.
18. Lewandowski G, Hobbs M, Geller A. Evidence that deficient IFN-gamma production is a biological basis of herpes simplex virus type-2 neurovirulence. J Neuroimmunol 1998;81:66-75.
19. Koelle DM, Frank JM, Johnson ML, et al. Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions. J Virol 1998;72:7476-83.
20. + CTL clones recognize HSV-2-infected fibroblasts after treatment with IFN-gamma or when virion host shutoff functions are disabled. J Immunol 1996;156:3901-10.
21. Morrison LA, Knipe DM. Contributions of antibody and T- cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1. Virology 1997;239:315-26.
22. Bravo FJ, Bourne N, Harrison CJ, et al. Effect of antibody alone and combined with acyclovir on neonatal herpes simplex virus infection in guinea pigs. J Infect Dis 1996;173:1-6.
23. Sanna PP, De Logu A, Williamson RA, et al. Protection of nude mice by passive immunization with a type-common human recombinant monoclonal antibody against HSV. Virology 1996.215:101-6.
24. Mitchell BM, Stevens JG. Neuroinvasive properties of herpes simplex virus type 1 glycoprotein variants are controlled by the immune response. J Immunol 1996;156:246-55.
25. Kohl S, Strynadka NC, Hodges RS, et al. Analysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B. J Clin Invest 1990;86:273-8.
26. Metcalf JF, Koga J, Chatterjee S, et al. Passive immunization with monoclonal antibodies against herpes simplex virus glycoproteins protects mice against herpetic ocular disease. Curr Eye Res 1987;6:173-7.
27. Ashley RL, Dalessio J, Burchett S, et al. Herpes simplex virus-2 (HSV-2) type-specific antibody correlates of protection in infants exposed to HSV-2 at birth. J Clin Invest 1992;90:511-4.
28. Ashley R, Benedetti J, Corey L. Humoral immune response to HSV-1 and HSV-2 viral proteins in patients with primary genital herpes. J Med Virol 1985;17:153-66.
29. Bonneau RH, Jennings SR. Modulation of acute and latent herpes simplex virus infection in C57BL/6 mice by adoptive transfer of immune lymphocytes with cytolytic activity. J Virol 1989;63:1480-4.
30. Jennings SR, Bonneau RH, Smith PM, et al. CD4-positive T lymphocytes are required for the generation of the primary but not the secondary CD8-positive cytolytic T lymphocyte response to herpes simplex virus in C57BL/6 mice. Cell Immunol 1991;133:234-52.
31. Larsen HS, Feng MF, Horohov DW, et al. Role of T-lymphocyte subsets in recovery from herpes simplex virus infection. J Virol 1984;50:56-9.
32. Larsen HS, Russell RG, Rouse BT. Recovery from lethal herpes simplex virus type 1 infection is mediated by cytotoxic T lymphocytes. Infect Immun 1983;41:197-204.
33. Sethi KK, Omata Y, Schneweis KE. Protection of mice from fatal herpes simplex virus type 1 infection by adoptive transfer of cloned virus-specific and H-2-restricted cytotoxic T lymphocytes. J Gen Virol 1983;64:443-7.
34. Kapoor AK, Nash AA, Wildy P, et al. Pathogenesis of herpes simplex virus in congenitally athymic mice: the relative roles of cell-mediated and humoral immunity. J Gen Virol 1982;60:25-233.
35. Manickan E, Rouse BT. Roles of different T-cell subsets in control of herpes simplex virus infection determined by using T-cell-deficient mouse-models. J Virol 1995;69:8178-9.
36. 8+ cytotoxic T- lymphocyte responses. Proc Natl Acad Sci USA 1997;94:10289-94.
37. Fruh K, Ahn K, Djaballah H, et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995;375:415-8.
38. Hill A, Jugovic P, York I, et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995;375:411-5.
39. Tomazin R, van School NE, Goldsmith K, et al. Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP. J Virol 199872:2560-3.
40. + T-cell response. J Exp Med 1998;187:341-8.
41. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337:1105-11.
42. Gibson JJ, Hornung CA, Alexander GR, et al. A cross-sectional study of herpes simplex virus types 1 and 2 in college students: occurrence and determinants of infection. J Infect Dis 1990;162:306-12.
43. Koutsky LA, Ashley RL, Holmes KK, et al. The frequency of unrecognized type 2 herpes simplex virus infection among women: implications for the control of genital herpes. Sex Transm Dis 1990;17:90-4.
44. Cowan FM, Johnson AM, Ashley R, et al. Relationship between antibodies to herpes simplex virus (HSV) and symptoms of HSV infection. J Infect Dis 1996;174:470-5.
45. Lyttle PH. Surveillance report: disease trends at New Zealand sexually transmitted disease clinics 1977-1993. Genitourin Med 1994;70:329-35.
46. Mertz GJ, Benedetti J, Ashley R, et al. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992;116:197-202.
47. Bryson Y, Dillon M, Bernstein DI, et al. Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J Infect Dis 1993;167:942-6.
48. Rattray MC, Corey L, Reeves WC, et al. Recurrent genital herpes among women: symptomatic v. asymptomatic viral shedding. Br J Vener Dis 1978;54:262-5.
49. Adam E, Kaufman RH, Mirkovic RR, et al. Persistence of virus shedding in asymptomatic women after recovery from herpes genitalis. Obstet Gynecol 1979;54:171-3.
50. Brock BV, Selke S, Benedetti J, et al. Frequency of asymptomatic shedding of herpes simplex virus in women with genital herpes. JAMA 1990;263:418-20.
51. Koelle DM, Benedetti J, Langenberg A, et al. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med 1992;116:433-7.
52. WaLd A, Corey L, Cone R, et al. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest 1997;99:1092-7.
53. Stamm WE, Handsfield HH, Rompalo AM, et al. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA 1988;260:1429-33.
54. Hook EW III, Cannon RO, Nahmias AJ, et al. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. J Infect Dis 1992;165:251-5.
55. Boulos R, Ruff AJ, Nahmias A, et al. Herpes simplex virus type 2 infection, syphilis, and hepatitis B virus infection in Haitian women with human immunodeficiency virus type 1 and human T lymphotropic virus type I infections: the Johns Hopkins University (JHU)/Centre pour le Developpement et la Sant'e (CDS) HIV Study Group. J Infect Dis 1992;166:418-20.
56. Gwanzura L, McFarland W, Alexander D, et al. Association between human immunodeficiency virus and herpes simplex virus type 2 seropositivity among male factory workers in Zimbabwe. J Infect Dis 1998;177:481-4.
57. Schacker T, Ryncarz AJ, Goddard J, et al. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998;280:61-6.
58. Lafferty WE, Coombs RW, Benedetti J, et al. Recurrences after oral and genital herpes simplex virus infection: influence of site of infection and viral type. N Engl J Med 1987;316:1444-9.
59. Sucato G, WaLd A, Wakabayashi E, et al. Evidence of latency and reactivation of both herpes simplex virus (HSV)-1 and HSV-2 in the genital region. J Infect Dis 1998;177:1069-72.
60. Aurelian L, Kokuba H, Burnett JW. Understanding the pathogenesis of HSV-associated erythema multiforme. Dermatology 1998;197:219-22.
61. Huff JC, Weston WL. Recurrent erythema multiforme. Medicine (Baltimore) 1989;68:133-40.
62. Bachmeyer C, de la Blanchardiere A, Lepercq J, et al. Recurring episodes of meningitis (Mollaret's meningitis) with one showing an association with herpes simplex virus type 2. J Infect 1996;32:247-8.
63. Chambers ST, Powell KF, Croxson MC, et al. Demonstration of herpes simplex type 2 in the cerebrospinal fluid of two patients with recurrent lymphocytic meningitis. N Z Med J 1994;107:367-9.
64. Whitley RJ, Neonatal herpes simplex virus infections: pathogenesis and therapy. Pathol Biol 1992;40:729-34.
65. Whitley R, Arvin A, Prober C, et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections: the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med 1991;324:450-4.
66. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997;337:509-15.
67. Sullivan-Bolyai JZ, Hull HF, Wilson C, et al. Presentation of neonatal herpes simplex virus infections: implications for a change in therapeutic strategy. Pediatr Infect Dis 1986;5:309-14.
68. Slomka MJ, Emery L, Munday PE, et al. A comparison of PCR with virus isolation and direct antigen detection for diagnosis and typing of genital herpes. J Med Virol 1998;55:177-83.
69. Groen J, Van Dijk G, Niesters HG, et al. Comparison of two enzyme-linked immunosorbent assays and one rapid immunoblot assay for detection of herpes simplex virus type 2-specific antibodies in serum. J Clin Microbiol 1998;36:845-7.
70. Ashley RL, Wu L, Pickering JW, et al. Premarket evaluation of a commercial glycoprotein G-based enzyme immunoassay for herpes simplex virus type-specific antibodies. J Clin Microbiol 1998;36:294-5.
71. Fairley I, Monteiro EF. Patient attitudes to type specific serological tests in the diagnosis of genital herpes. Genitourin Med 1997;73:259-62.
72. Langenberg A, Benedetti J, Jenkins J, et al. Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. Ann Intern Med 1989;110:882-7.
73. Whitley RJ, Kimberlin DW. Treatment of viral infections during pregnancy and the neonatal period. Clin Perinatol 1997;24:267-83.
74. Elion GB, Furman PA, Fyfe JA, et al. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 1977;74:5716-20.
75. Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996;52:754-72.
76. Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection: AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis 1998;177:48-56.
77. Crumpacker C. The pharmacological profile of famciclovir. Semin Dermatol 1996;15:14-26.
78. Mertz GJ, Critchlow CW, Benedetti J, et al. Double-blind placebo-controlled trial of oral acyclovir in first- episode genital herpes simplex virus infection. JAMA 1984;252:1147-51.
79. Fife KH, Barbarash RA, Rudolph T, et al. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double- blind, randomized clinical trial: the Valaciclovir International Herpes Simplex Virus Study Group. Sex Transm Dis 1997;24:481-6.
80. Bryson YJ. Current status and prospects for oral acyclovir treatment of first episode and recurrent genital herpes simplex virus. J Antimicrob Chemother 1983;12:61S-5S.
81. Corey L, Benedetti J, Critchlow C, et al. Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy. J Antimicrob Chemother 1983;12:79S-88S.
82. Bryson Y, Dillon M, Lovett M, et al. Treatment of first episode genital HSV with oral acyclovir: long term follow-up of recurrences. A preliminary report. Scand J Infect Dis Suppl 1985;47:70-5.
83. Peacock JE Jr, Kaplowitz LG, Sparling PF, et al. Intravenous acyclovir therapy of first episodes of genital herpes: a multicenter double-blind, placebo-controlled trial. Am J Med 1988;85:301-6.
84. Thackray AM, Field HJ. Famciclovir and valaciclovir differ in the prevention of herpes simplex virus type 1 latency in mice: a quantitative study. Antimicrob Agents Chemother 1998;42:1555-62.
85. Thackray AM, Field HJ. Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model. Antimicrob Agents Chemother 1996;40:846-51.
86. Thackray AM, Field HJ. Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reac-tivation from latency. J Infect Dis 1996;173:291-9.
87. Tyring SK, Douglas JM Jr, Corey L, et al. A randomized, placebo-controlled comparison of oral valaciclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group. Arch Dermatol 1998;134:185-91.
88. Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus acyclovir in patient-initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. Genitourin Med 1997;73:110-6.
89. Sacks SL, Aoki FY, Diaz-Mitoma F, et al. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA 1996;276:44-9.
90. Spruance SL, Tyring SK, DeGregorio B, et al. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med 1996;156:1729-35.
91. Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA 1984;251:2103-7.
92. Baker DA, Blythe JG, Kaufman R, et al. One-year suppression of frequent recurrences of genital herpes with oral acyclovir. Obstet Gynecol 1989;73:84-7.
93. Mertz GJ, Jones CC, Mills J, et al. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. JAMA 1988;260:201-6.
94. Halsos AM, Salo OP, Lassus A, et al. Oral acyclovir suppression of recurrent genital herpes: a double-blind, placebo-controlled, crossover study. Acta Derm Venereol 1985;65:59-63.
95. Straus SE, Takiff HE, Seidlin M, et al. Suppression of frequently recurring genital herpes: a placebo-controlled double-blind trial of oral acyclovir. N Engl J Med 1984;310:1545-50.
96. Douglas JM, Critchlow C, Benedetti J, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984;310:1551-6.
97. Goldberg LH, Kaufman R, Kurtz TO, et al. Long-term suppression of recurrent genital herpes with acyclovir: a 5-year benchmark. Acyclovir Study Group. Arch Dermatol 1993;129:582-7.
98. Baker DA. Long-term suppressive therapy with acyclovir for recurrent genital herpes. J Int Med Res 1994;22:24A-32A.
99. Diaz-Mitoma F, Sibbald RG, Shafran SD, et al. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. JAMA 1998;280:887-92.
100. Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: a double-blind, placebo-controlled trial. Ann Intern Med 1998;128:21-8.
101. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a largescale dose range-finding study. International Valaciclovir HSV Study Group. J Infect Dis 1998;178:603-10.
102. Patel R, Bodsworth NJ, Woolley P, et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group. Genitourin Med 1997;73:105-9.
103. Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: a multicenter, doubleblind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Arch Intern Med 1997;157:343-9.
104. Scott LL, Alexander J. Cost-effectiveness of acyclovir suppression to prevent recurrent genital herpes in term pregnancy. Am J Perinatol 1998;15:57-62.
105. Scott LL, Sanchez PJ, Jackson GL, et al. Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Obstet Gynecol 1996;87:69-73.
106. Darby G, Field HJ, Salisbury SA. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir resistance. Nature 1981;289:81-3.
107. Chrisp P, Clissold SP. Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 1991;41:104-29.
108. Balfour HH Jr, Benson C, Braun J, et al. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr Hum Retrovirol 1994;7:254-60.
109. Safrin S, Kemmerly S, Plotkin B, et al. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis 1994;169:193-6.
110. Lalezari J, Schacker T, Feinberg J, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997;176:892-8.
111. Martinez CM, Luks-Golger DB. Cidofovir use in acyclovir-resistant herpes infection. Ann Pharmacother 1997;31:1519-21.
112. Lalezari JP, Drew WL, Glutzer E, et al. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J Infect Dis 1994;170:570-2.
113. Snoeck R, Andrei G, Gerard M, et al. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin Infect Dis 1994;18:570-8.
114. Wald A, Zeh J, Barnum G, et al. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996;124:8-15.
115. Blower SM, Porco TC, Darby G. Predicting and preventing the emergence of antiviral drug resistance in HSV-2. Nat Med 1998;4:673-8.
116. Scott TF. Historical aspects of herpes simplex infections: II. Int J Dermatol 1986;25:127-34.
117. Douglas JM, Vontver LA, Stamm WE, et al. Ineffectiveness and toxicity of BCG vaccine for the prevention of recurrent genital herpes. Antimicrob Agents Chemother 1985;27:203-6.
118. Blank H, Haines HG. Experimental human reinfection with herpes simplex virus. J Invest Dermatol 1973;61:223-5.
119. Weitgasser H. Controlled clinical study of the herpes antigens LUPIDON H and LUPIDON G. Z Hautkr 1977;52:625-8.
120. Skinner GR, Woodman C, Hartley C, et al. Early experience with "antigenoid" vaccine Ac NFU1(S-) MRC towards prevention or modification of herpes genitalis. Dev Biol Stand 1982;52:333-44.
121. Skinner GR, Fink CG, Cowan M, et al. Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine. Med Microbiol Immunol (Berl) 1987;176:161-8.
122. Skinner GR, Fink C, Melling J, et al. Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis. Med Microbiol Immunol (Berl) 1992;180:305-20.
123. Skinner GR, Turyk ME, Benson CA, et al. The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis: report of a prospective double-blind placebo-controlled trial. Med Microbiol Immunol (Berl) 1997;186:31-6.
124. Mertz GJ, Ashley R, Burke RL, et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis 1990;161:653-60.
125. Stanberry LR, Bernstein DI, Burke RL, et al. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 1987;155:914-20.
126. Stanberry LR, Harrison CJ, Bernstein DI, et al. Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy. Antiviral Res 1989;11:203-14.
127. Burke RL, Goldbeck C, Ng P, et al. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J Infect Dis 1994;170:1110-9.
128. Straus SE, Corey L, Burke RL, et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994;343:1460-3.
129. Straus SE, Wald A, Kost RG, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo- controlled vaccine trial. J Infect Dis 1997;176:1129-34.
130. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988;158:602-14.
131. Meignier B, Martin B, Whitley RJ, et al. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020; II: studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis 1990;162:313-21.
132. Farrell HE, McLean CS, Harley C, et al. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J Virol 1994;68:927-32.
133. McLean CS, Erturk M, Jennings R. et al. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis 1994;170:1100-9.
134. Boursnell ME, Entwisle C, Blakeley D, et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 1997;175:16-25.
135. Da Costa XJ, Bourne N, Stanberry LR, et al. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology 1997;232:1-12.
136. Spector FC, Kern ER, Palmer J, et al. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J Infect Dis 1998;177:1143-54.
137. Nass PH, Elkins KL, Weir JP. Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins. J Infect Dis 1998;178:611-7.
138. Hariharan MJ, Driver DA, Townsend K, et al. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol 1998;72:950-8.
139. McClements WL, Armstrong ME, Keys RD, et al. The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs. Vaccine 1997;15:857-60.
140. McClements WL, Armstrong ME, Keys RD, et al. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Natl Acad Sci USA 1996;93:11414-20.
141. Wang R, Doolan DL, Le TP, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998;282:476-80.